TVAX-008 clinical trials
Also written TVAX-008.
How each study uses TVAX-008 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TVAX-008 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TVAX-008
- 5
Studies by the year they started
5 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Grand Theravac Life Sciences (Nanjing) Co., Ltd. (3) · Grand Theravac Life Sciences (Hangzhou) Co., Ltd. (1) · Ausper Biopharma Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses TVAX-008 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Not yet recruitingPhase 1/2Grand Theravac Life Sciences (Hangzhou) Co., Ltd.NCT07897448Written as TVAX-008
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Not yet recruitingPhase 1/2Ausper Biopharma Co., Ltd.NCT07876856Written as TVAX-008
- Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological ConversionActive, not recruitingEarly Phase 1Grand Theravac Life Sciences (Nanjing) Co., Ltd.NCT07204236Written as TVAX-008
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis BActive, not recruitingPhase 2Grand Theravac Life Sciences (Nanjing) Co., Ltd.NCT07190742Written as TVAX-008
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B PatientsActive, not recruitingPhase 2Grand Theravac Life Sciences (Nanjing) Co., Ltd.NCT07179653Written as TVAX-008
What changed recently
From the registry's own updates since Oct 18, 2026.